Go to deals
Healthcare | Private Equity

GMD PharmaSolutions has been acquired by McKesson Corporation

GMD PharmaSolutions, a portfolio company of Hammond, Kennedy, Whitney & Company (HKW), has been sold to McKesson Corporation for an undisclosed consideration.

GMD PharmaSolutions provides a one-stop solution for the management and distribution of pharmaceuticals, biological and medical devices in Canada.

McKesson is the oldest and largest healthcare company in the nation, serving more than 50% of US hospitals and 20% of physicians. The company delivers one third of all medications used daily in North America and has operations in more than 16 countries. McKesson's state-of-the-art network of distribution centers are strategically located across the USA, storing thousands of branded, generic and specialty pharmaceuticals and over-the-counter products from manufacturers around the globe. Its sophisticated online ordering platform and tools ensure availability, accuracy, on-time delivery and barcode tracking.

HKW is a private equity firm specializing in investments in later stage, mature, management buy-outs of privately owned businesses, subsidiaries, and divisions of corporations and public companies; industry consolidations; corporate divestitures; generational changes in ownership; recapitalization transactions; and growth equity investments. The firm seeks to invest in small middle-market companies with low risk of technological obsolescence. HKW is a generalist that seeks to invest in the medical devices, aerospace and defense, water infrastructure, oil and natural gas, telecommunication services, information technology, materials, specialty and recreational vehicles, automation processing equipment, industrial burners and combustion equipment, financials, healthcare, energy, nuclear, coal, niche manufacturing, and utility related infrastructure, with a focus on industrial manufacturing, services, and distribution companies. The firm prefers to invest in companies headquartered in North America. It seeks to invest from US$5 to more than US$150 million in companies having an enterprise value between US$10–175 million, generating revenues between US$20–200 million, with an EBITDA between US$2–30 million, and having operating cash flow of at least US$2 million. The platform transaction range is between US$20 to over US$150 million with no minimum for add-on acquisitions. It typically makes equity investments that result in acquisition of control and does not have a minimum criterion for add-on acquisitions.

One of Oaklins' member firms in the USA served as the exclusive financial advisor to GMD PharmaSolutions in its sale to McKesson Corporation.

Parties

Talk to the deal team

Michael S. Goldman

Managing Director
New York, United States
Oaklins TM Capital

Paul R. Smolevitz

Managing Director
New York, United States
Oaklins TM Capital

Vidur Kapur

Associate Director
New York, United States
Oaklins TM Capital

Related deals

INNOTEX has been acquired by Clearspring Capital Partners
Private Equity | Other Industries

INNOTEX has been acquired by Clearspring Capital Partners

INNOTEX, a manufacturer of personal protective equipment for firefighters and first responders, has completed a strategic partnership with Clearspring Capital Partners.

Learn more
GARAIO has been acquired by Netrics Group
Private Equity | TMT

GARAIO has been acquired by Netrics Group

Netrics Group has acquired GARAIO AG as a wholly owned subsidiary. GARAIO will continue to operate as an independent company under the umbrella of Netrics Group. With this acquisition, Netrics Group is further expanding its leading position as a provider of managed cloud and digital workplace solutions as well as consulting services.

Learn more
Aptic has received a minority investment from Sofiouest
Private Equity | Business Support Services

Aptic has received a minority investment from Sofiouest

The shareholders of Aptic have completed a primary minority LBO with Sofiouest.

Learn more